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• Four out of five (80%) of the world's population 
will contract some type of the virus once in their 
life via sexual contact [1]
• High risk types of HPV can cause cervical cancer 
in women as well as other cancers such as anal, 
mouth/throat and cancer of the penis in men [2]
HPV virus: a gender neutral 
killer
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HPV infection can be prevented
• Individuals who are not 
sexually active almost never 
develop genital HPV 
infections [3] 
• HPV vaccination before 
sexual activity can reduce 
the risk of infection by the 
HPV types targeted by the 
vaccine [4]
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Debate on vaccination strategies
Gender neutral vaccination
• Physicians recommend to 
vaccinate girls and boys
Selective vaccination
• Most of the National Health 
Systems in Europe continue to 
implement the selective 
immunization of 12-year-old 
girls only
• This policy decision is based 
purely on cost-effectiveness
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How are boys protected if they are not 
vaccinated?
Herd immunity
• The presence of enough 
immune (vaccinated) 
individuals in a community 
interrupts the transmission of 
an infective agent, thereby 
providing indirect protection to 
unvaccinated (susceptible) 
persons [5].
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Our research: critical review of cost 
effectiveness studies (n=8)
What is cost-effectiveness?
• Form of economic analysis that 
compares the relative costs and 
outcomes (effects) of different 
interventions.
• If the incremental cost of a new 
intervention results below a 
given threshold, then it is cost-
effective.
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Outcome 1: a matter of price
Sensitivity to boundary conditions
• All the cost-effectiveness studies 
resulted extremely sensitive to 
the inputs used to inform the 
models
• In particular, adding boys to HPV 
vaccination became cost 
effective in all models at a 
threshold price/vial
Threshold price per vaccine vial
€28
at 2015 values
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Outcome 2: ecological validity
How well the models reflect our 
society?
• Closed population or cohort 
models: no immigration allowed
• Behaviours relevant to sexual 
mixing [6] ignored:
• Sexual identity
• Concurrent partnerships
• Sex abroad
• Pay for sex
• Frequency of unprotected sex 
Implications
• The non-modelled behaviours related 
to sexual mixing may have produced 
an over-estimation of the impact of 
herd immunity [7]
• When we tested a credible hypothesis 
of 5% to 20% over-estimation of herd 
immunity, most of the scenarios 
including gender neutral vaccination 
became cost-effective.
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About a 12 year old boy
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In his life, an unvaccinated boy has a 4 to 5 % 
possibility to be unprotected by herd immunity…
Unlikely
low
Likely Unlikely
high
Possible
Fuzzy distribution of individual risk factors
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…when it counts the most
MSM                 PAY FOR SEX                SEX ABROAD
up to 44x risk of HPV infection
vs. general population [8]
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Conclusions
• The published cost effectiveness studies 
on HPV vaccination to boys are likely to 
over-estimate the benefits of herd effects 
on the unvaccinated population
• A relatively small (15 to 20%) over-
estimation of herd immunity obtained 
with selective immunisation could induce 
a significant error in the estimate of the 
cost-effectiveness of gender neutral 
immunisation.
Offering the HPV vaccination to both boys 
and girls would be the most effective 
option for improving public health. 
[Research Council UK, 2013]
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